Log In
BCIQ
Print this Print this
 

FLX925 (formerly AMG 925)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionSmall molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135), cyclin dependent kinase 4 (CDK4) and CDK6
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135) ; Cyclin dependent kinase (CDK)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat relapsed or refractory acute myelogenous leukemia (AML)
Regulatory Designation
PartnerFLX Bio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today